Dongun Anatek announced that it has submitted a clinical trial plan approval application to the Ministry of Food and Drug Safety for a non-invasive, non-blood-drawing saliva-based blood glucose measurement system.

The measurement principle involves calculating an estimated blood glucose value by measuring glucose concentration in saliva using an electrochemical method. The goal is to help high-risk groups—such as those with prediabetes, obesity, and overweight—periodically monitor their blood glucose for preventive purposes.

The clinical trial will be conducted simultaneously at three institutions, including Seoul Asan Medical Center and Seoul St. Mary's Hospital, with a patient recruitment target of 200 participants. The company plans to provide updates on the progress through future announcements.

Riding on this news, Dongun Anatek successfully staged a major reversal after four trading days. The Volatility Intervention Mechanism (VI) was triggered as many as three times during the session, and the stock is currently trading at a price more than 15% higher. Close attention is needed regarding the market impact of the clinical trial plan approval filing and the future stock price trend.

[This article was written for informational purposes and does not constitute investment advice or a recommendation to buy or sell any specific stock. The stock may exhibit high volatility due to changes in supply and demand. The final investment decision and responsibility lie with the investor.]